These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36939530)

  • 21. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.
    Weiten R; Niemann M; Below E; Friker LL; Ralser DJ; Toma M; Kristiansen G; Hahn O; Zechel S; Grünwald V; Bald T; Siewert J; Pietsch T; Ritter M; Hölzel M; Eckstein M; Alajati A; Krausewitz P; Klümper N
    Cancer Med; 2024 Jun; 13(12):e7320. PubMed ID: 38895886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
    Scher HI; Graf RP; Schreiber NA; Jayaram A; Winquist E; McLaughlin B; Lu D; Fleisher M; Orr S; Lowes L; Anderson A; Wang Y; Dittamore R; Allan AL; Attard G; Heller G
    JAMA Oncol; 2018 Sep; 4(9):1179-1186. PubMed ID: 29955787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.
    Ashizawa T; Nagata M; Nakamura S; Hirano H; Nagaya N; Lu Y; Horie S
    Sci Rep; 2022 Oct; 12(1):18016. PubMed ID: 36289357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
    Gurioli G; Conteduca V; Brighi N; Scarpi E; Basso U; Fornarini G; Mosca A; Nicodemo M; Banna GL; Lolli C; Schepisi G; Ravaglia G; Bondi I; Ulivi P; De Giorgi U
    BMC Med; 2022 Jan; 20(1):48. PubMed ID: 35101049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients.
    Schlack K; Seitzer K; Wüstmann N; Humberg V; Grundmann N; Steinestel J; Tiedje D; Rahbar K; Krabbe LM; Bögemann M; Schrader AJ; Bernemann C
    Sci Rep; 2022 Jul; 12(1):11846. PubMed ID: 35831403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
    Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
    Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.
    Isebia KT; Mostert B; Belderbos BPS; Buck SAJ; Helmijr JCA; Kraan J; Beaufort CM; Van MN; Oomen-de Hoop E; Sieuwerts AM; van IJcken WFJ; van den Hout-van Vroonhoven MCGN; Brouwer RWW; Oole E; Hamberg P; Haberkorn BCM; Helgason HH; de Wit R; Sleijfer S; Mathijssen RHJ; Martens JWM; Jansen MPHM; van Riet J; Lolkema MP
    Eur J Cancer; 2022 Dec; 177():33-44. PubMed ID: 36323051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
    Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY; Dong Q; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.
    Pacheco-Orozco RA; Montealegre-Páez L; Cayol F; Martínez-Gregorio H; Oliver J; Frecha C; Vaca-Paniagua F; Perdomo S
    Oncologist; 2020 Dec; 25(12):e1990-e1995. PubMed ID: 32721059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    Sperger JM; Emamekhoo H; McKay RR; Stahlfeld CN; Singh A; Chen XE; Kwak L; Gilsdorf CS; Wolfe SK; Wei XX; Silver R; Zhang Z; Morris MJ; Bubley G; Feng FY; Scher HI; Rathkopf D; Dehm SM; Choueiri TK; Halabi S; Armstrong AJ; Wyatt AW; Taplin ME; Zhao SG; Lang JM
    J Clin Oncol; 2021 Sep; 39(26):2926-2937. PubMed ID: 34197212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
    Shao C; Yu B; Liu Y
    Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
    Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J
    Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
    Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
    Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer.
    Zavridou M; Smilkou S; Tserpeli V; Sfika A; Bournakis E; Strati A; Lianidou E
    Clin Chem; 2022 Oct; 68(10):1323-1335. PubMed ID: 36093578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.